Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 30.65

-2.9%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mcbio who wrote (461)	1/6/2010 9:36:28 AM
From: tuck	Read Replies (1) of 566

Some analysts think Rigel will sign a partnership this year. It would be interesting to dig into SYK as a supressor for other cancer types. If it was limited to breast cancer, at least the male part of the market would still be there . . . definitely a less manageable side effect than mild hypertensive action, and I've stayed away for similar reasons. Gastric cancer cells are also in play. And also this one: pancreatic ductal adenocarcinoma. Don't know how common that is. Incidentally, there is an article from 2005 suggesting SYK as a supressor of breast cancer tumor cells. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next